TMEM60 and neoplasm: We found that the clinical characteristics of patients with high TMEM60 expression levels were mainly IDH wild-type, 1p19q non-codel, WHO grade IV, >42 years of age, increased immune cells and stromal cells, decreased tumor purity, and increased activation of immune cells or pathways.